Effect of Ibuprofen on Blood Pressure Control by Propranolol and Bendrofluazide

The effect of 1600 mg/day ibuprofen in two groups of patients with hypertension controlled by either propranolol or bendrofluazide was studied in a double-blind, double-placebo, randomized crossover trial. No significant difference in blood pressure was found at the end of the crossover period in either group, suggesting that the routine co-administration of ibuprofen does not attenuate the antihypertensive effect of thiazide diuretics or propranolol. Significant weight gain, attributable to fluid retention, had occurred in the bendrofluazide-treatment group by the end of the drug-free washout period. No significant change in mean weight occurred in the crossover stages in either group, although substantial weight gain was noted during ibuprofen treatment in two patients given bendrofluazide and one given propranolol. Biochemical variables were unaffected by ibuprofen throughout the crossover period. This study suggests that ibuprofen may be administered routinely to patients receiving thiazides or propranolol without loss of control of the anti-hypertensive action of these drugs but it is recommended that individuals are monitored for possible weight gain or an increase in diastolic blood pressure.

Download Full-text

Faculty Opinions recommendation of Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718338720.793493657 ◽

2014 ◽

Author(s):

Andreas Hoeft

Keyword(s):

Blood Pressure ◽

Coronary Artery ◽

Coronary Artery Bypass Grafting ◽

Coronary Artery Bypass ◽

Blood Pressure Control ◽

Artery Bypass ◽

Pressure Control ◽

Double Blind Study ◽

Bypass Grafting ◽

Double Blind

Download Full-text

Acute intake of quercetin from onion skin extract does not influence postprandial blood pressure and endothelial function in overweight-to-obese adults with hypertension: a randomized, double-blind, placebo-controlled, crossover trial

European Journal of Nutrition ◽

10.1007/s00394-016-1185-1 ◽

2016 ◽

Vol 56 (3) ◽

pp. 1347-1357 ◽

Cited By ~ 15

Author(s):

Verena Brüll ◽

Constanze Burak ◽

Birgit Stoffel-Wagner ◽

Siegfried Wolffram ◽

Georg Nickenig ◽

...

Keyword(s):

Blood Pressure ◽

Endothelial Function ◽

Crossover Trial ◽

Skin Extract ◽

Obese Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Onion Skin ◽

Acute Intake

Download Full-text

Comparative Study of Satisfaction and Acceptability between Using Menstrual Cup versus Sanitary Pads in Health Care Personnel: A Randomized Crossover Trial

Journal of the Medical Association of Thailand ◽

10.35755/jmedassocthai.2021.01.11485 ◽

2021 ◽

Vol 104 (1) ◽

pp. 1-9

Keyword(s):

Health Care ◽

Sexual Intercourse ◽

Crossover Trial ◽

Health Care Personnel ◽

The Past ◽

Randomized Crossover Trial ◽

Significant Difference ◽

Hcp Materials ◽

Group A ◽

Sanitary Pads

Background: In the past decade, menstrual cups (MC) have become increasingly popular in many countries but there was no previous reporting on MC usage in Thailand. Objective: To evaluate and compare the satisfaction and acceptability of using MC and sanitary pads (SP) in health care personnel (HCP). Materials and Methods: Participants were HCP in Bhumibol Adulyadej Hospital who were willing to participate in the study between October 2019 and March 2020. They were randomly assigned into groups A and B. During the first three cycles of menstruation, participants in group A and B used SP and MC, respectively. In the later three cycles of menstruation, they were switched from SP to MC and vice versa. The demographic and menstrual characteristics were recorded. Satisfaction was evaluated by using the five-point Likert scale. Acceptability of MC usage was recorded on the sixth cycle questionnaire. Results: Ninety-eight HCP were recruited and equally divided into two groups (A and B). Acceptability for MC was significantly lower than SP (89 versus 100 percent, respectively). Participants who had regular sexual intercourse had more acceptability with MC than those who had no regular intercourse (98.4 versus 68.7 percent, respectively). Participants reported more significant satisfaction for MC than SP in terms of leakage prevention, cleaning, odor prevention, land activity, daily activity, comfortable sleep, and overall satisfaction. Contact dermatitis associated with MC was less than with SP with a statistically significant difference. Conclusion: Acceptability for MC was lower than SP. MC’s acceptability was preferred among HCPs with regular sexual intercourse. MC had higher satisfaction and less side effects than SP. Keywords: Acceptability, Menstrual cup, Menstruation, Sanitary pads, Satisfaction

Download Full-text

Abstract P060: Angiotensin AT1A Receptors on Vasopressin-Expressing Cells are Dispensable for DOCA-salt Hypertension

Hypertension ◽

10.1161/hyp.66.suppl_1.p060 ◽

2015 ◽

Vol 66 (suppl_1) ◽

Author(s):

Jeremy A Sandgren ◽

Danny W Linggonegoro ◽

Kristin E Claflin ◽

Nicole A Pearson ◽

Gary L Pierce ◽

...

Keyword(s):

Blood Pressure ◽

Blood Pressure Control ◽

Specific Activity ◽

Fluorescent Microscopy ◽

Renin Angiotensin System ◽

Pressure Control ◽

Fluorescent Reporter ◽

Significant Difference ◽

Low Renin Hypertension ◽

Salt Hypertension

Increased blood pressure in the deoxycorticosterone acetate (DOCA)-salt model of low-renin hypertension is correlated with increased vasopressin (AVP) secretion, and is sensitive to inhibition of the brain renin-angiotensin system (RAS). Further, AVP-deficient Brattleboro rats are largely resistant to DOCA-salt hypertension. These findings lead us to hypothesize a role for AT1A receptors localized to AVP-expressing neurons in the control of AVP secretion, specifically in low-renin hypertension. Blood pressure was assessed via tail-cuff plesthysmography and total daily AVP secretion assessed via urine copeptin in mice with specific disruption of the AT1A gene in AVP-expressing cells (AVP-Cre x AT1Aflox/flox mice, “KO”) under both baseline and DOCA-salt treatment conditions. Specific activity of Cre-recombinase within the paraventricular and supraoptic nuclei of AVP-Cre transgenic mice was confirmed by fluorescent microscopy in brain sections from mice expressing a conditional fluorescent reporter (AVP-Cre x ROSA-stopflox-tdTomato mice). At baseline, AVP secretion (via urine copeptin) trended downward with large variation (control n=17, 363±182 vs KO n=5, 33±11 pg/day; p>0.05) but there was no significant difference in blood pressure (control n=27, 107±1.3 vs KO n=12, 111±2.2 mmHg; p>0.05) compared to littermate controls. In response to DOCA-salt, blood pressure (control n=23, +10.35±2.1 vs KO n=8, +12.91±2.0; p>0.05), urine output (control n=23, +12.65±0.8 vs KO n=9, +12.73±1.5 g/day; p>0.05), and fluid intake (control n=23, +16.17±1.3 vs KO n=9, +14.83±2.5 mL/day; p>0.05) increased normally in KO mice. Preliminary findings indicate normal or possibly exaggerated urine copeptin levels in KO mice following DOCA-salt, and an exaggerated AVP release in response to increasing serum osmolality. Collectively, these data suggest that AT1A receptors on AVP expressing cells are required to mediate baseline secretion of AVP, but that these receptors are dispensable for DOCA-salt mediated increases in circulating AVP and blood pressure.

Download Full-text

Solumedrol Treatment for Severe Sepsis in Humans with a Blunted Adrenocorticotropic Hormone-Cortisol Response: A Prospective Randomized Double-Blind Placebo-Controlled Pilot Clinical Trial

Journal of Intensive Care Medicine ◽

10.1177/08850666211038883 ◽

2021 ◽

pp. 088506662110388

Author(s):

Divya Birudaraju ◽

Sajad Hamal ◽

John A. Tayek

Keyword(s):

Blood Pressure ◽

Clinical Trial ◽

Adrenocorticotropic Hormone ◽

Serum Cortisol ◽

High Dose ◽

Cortisol Response ◽

Acth Stimulation ◽

Double Blind ◽

Significant Difference ◽

To Receive

Purpose To test the benefits of Solumedrol treatment in sepsis patients with a blunted adrenocorticotropic hormone (ACTH)-cortisol response (delta <13 µg/dL) with regard to the number of days on ventilator, days on intravenous blood pressure support, length of time in an intensive care unit (ICU), 14-day mortality, and 28-day mortality. The trial was prospective, randomized, and double-blind. As part of a larger sepsis trial, 54 patients with sepsis had an intravenous ACTH stimulation test using 250 µg of ACTH, and serum cortisol was measured at times 0, 30, and 60 min. Eleven patients failed to increase their cortisol concentration above 19.9 µg/dL and were excluded from the clinical trial as they were considered to have adrenal insufficiency. The remaining 43 patients had a baseline cortisol of 32 ± 1 µg/dL increased to 38 ± 3 µg/dL at 30 min and 40 ± 3 at 60 min. All cortisol responses were <12.9 µg/dL between time 0 and time 60, which is defined as a blunted cortisol response to intravenous ACTH administration. Twenty-one were randomized to receive 20 mg of intravenous Solumedrol and 22 were randomized to receive a matching placebo every 8 h for 7-days. There was no significant difference between the two randomized groups. Data analysis was carried out bya two-tailed test and P < .05 as significant. Results Results: The mean age was 51 ± 2 (mean ± SEM) with 61% female. Groups were well matched with regard to APACHE III score in Solumedrol versus placebo (59 ± 6 vs 59 ± 6), white blood cell count (18.8 ± 2.2 vs 18.6 ± 2.6), and incidence of bacteremia (29 vs 39%). The 28-day mortality rate was reduced in the Solumedrol treated arm (43 ± 11 vs 73 ± 10%; P < .05). There was no change in days in ICU, days on blood pressure agents, or days on ventilator. Seven days of high-dose intravenous Solumedrol treatment (20 mg every 8 h) in patients with a blunted cortisol response to ACTH was associated with an improved 28-day survival. This small study suggests that an inability to increase endogenous cortisol production in patients with sepsis who are then provided steroid treatment could improve survival.

Download Full-text